ASCO, EHA et ICML 2021

CNS Relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL

Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA

Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA

First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, The French real-life database for CAR-T cells in hematologic malignancies

Prospective Evaluation of Lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA Group

Early Positron Emission Tomography Response-Adapted Treatment in Localized Diffuse Large B-Cell Lymphoma (aaIPI=0): Results of the Phase 3 LYSA LNH 09-1B Trial

Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study)

Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL): clinico-pathological analysis of a multicenter European cohort

Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients : a LYSA study

First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, a French real-life database for CAR-T cells in hematologic malignancies

Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Marginal Zone Lymphoma: primary analysis of a phase 2 trial from LYSA

Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA

Circulating tumor DNA load and total metabolic tumor volume in Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP – From REMARC, a LYSA study

High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS – From the REMARC study

Selinexor in Combination with R-GDP for Patients with Relapsed/ Refractory B-Cell Lymphoma: Preliminary results of the SELINDA phase Ib LYSA study

Long-term outcomes of elderly patients treated with frontline R-CHOP: Update of the LNH03-6B trial

Impact of DUSP22 rearrangement on the prognosis of systemic ALK-negative anaplastic large cell lymphoma : a LYSA and TENOMIC study

Brentuximab vedotin as consolidation treatment in patients with stage I/II classical Hodgkin’s lymphoma and a positive FDG-PET after 2 cycles of ABVD : a LYSA phase 2 study

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA group

Gender disparities in quality of life of French patients one year after the diagnosis of Lymphoma, a LYSA study

A widespread T-cell exhaustion pattern is frequent in the tumor microenvironment of relapsed/refractory B-cell Lymphoma patients and could be circumvented by PDL1 blockade